PTGX
Protagonist Therapeutics, Inc
$140.85
+9.35 (+7.11%)
At close · Jul 7
Market Cap
$9.06B
Shares
64,311,373
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$140.85
Open$132.59
Day$130.69–141.08
52W$49.38–141.08
Avg vol 30d752K
Short int7.7M · 12.0% float · 11.6d
Short vol89%
Last earningsMay 5, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 5
Equibles Rating
blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
High
Market backdrop
VIX 16.1 · calm
Equity put/call 0.69
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+55%
above
Price vs 50-day avg
+32%
above
RSI (14)
84
overbought
MACD trend
Positive
52-week position
100%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+45%
trailing
6-month return
+76%
trailing
YTD return
+61%
this year
Relative strength
+68%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $107 › 200d $91 — 50d above 200d
Institutional flow
Accumulating
6 of 322 funds reported for Jun 30 · net +946 sh shares · +2 new
Insider flow
Distributing
Net -$8.0M over 90 days · 100% sells
Short interest
Rising
12.02% of float · ▲ +4.3% MoM · 11.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
322 holders — near 3-yr high, broad support
Squeeze score
74
high risk · 0–100
Fundamentals
EPS growth
−148%
Y/Y
Free cash flow
$56.1M
Balance sheet
$118.6M
net cash
Quant / Vol
risk profile
Volatility
51%
annualized · 1-yr
Max drawdown
−16%
past year
ATR
3.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Up next
Next earnings call
Aug 5, 2026
Est · unconfirmed
· in 4 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 5, 2026
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+55%
Bullish
Price vs 50-day avg
+32%
Bullish
RSI (14)
84
Bearish
MACD trend
Positive
Bullish
52-week position
100%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $107 › 200d $91 — 50d above 200d
Institutional flow
Accumulating
6 of 322 funds reported for Jun 30 · net +946 sh shares · +2 new
Insider flow
Distributing
Net -$8.0M over 90 days · 100% sells
Short interest
Rising
12.02% of float · ▲ +4.3% MoM · 11.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
322 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $49
Now $141 · 100%
52-wk high $141
vs 200-day avg +55%
vs 50-day avg +32%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PTGX
this stock
Protagonist Therapeutics, Inc
|
$9.06B | +61.3% | — | — | 12.0% |
|
ONC
BeOne Medicines Ltd.
|
$446.53B | +1.7% | +22179.2% | 908.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$132.55B | +15.2% | +46.2% | 31.0 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$70.90B | -12.3% | +20.8% | 16.5 | 3.2% |
|
ARGX
Argenx SE
|
$57.49B | +9.4% | — | — | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PTGX | +15.8% | +44.6% | +75.5% | +14.9% | +61.3% |
| SPY | +0.9% | +1.4% | +7.6% | +0.1% | +9.7% |
| vs SPY | +14.9% | +43.3% | +68.0% | +14.8% | +51.6% |